DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for trichothiodystrophy 3, photosensitive — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTrichothiodystrophy 3, photosensitive maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for trichothiodystrophy 3, photosensitive is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
general transcription factor IIH subunit 5 (GTF2H5) — GTF2H5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7NVV · 2.9 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Trichothiodystrophy is a rare autosomal recessive disorder defined by brittle, cysteine-deficient hair that shows tiger-tail banding under polarised light. Approximately half of patients are photosensitive, and this subset is caused by mutations in the XPB, XPD or p8/TTDA genes, which encode subunits of the DNA repair/transcription factor TFIIH. The mutations disturb the helicase/ATPase activity of XPB and XPD, impairing both nucleotide excision repair and transcription, and also disrupt the architecture of the TFIIH complex, reducing its ability to transactivate certain nuclear receptor-responsive genes. The photosensitive form is sometimes described by the acronym PIBIDS (photosensitivity, ichthyosis, brittle hair, intellectual impairment, decreased fertility, short stature), as illustrated by a 2018 report of two Brazilian siblings with marked photosensitivity.
A 2012 case report describes a photosensitive TTD patient with complex cerebral abnormalities, noting that most mutations in the photosensitive form map to ERCC2/XPD or ERCC3/XPB on chromosome 19, and that the DNA repair defect can be classified by the specific mutation. In contrast, a 2025 report presents the second known case of type 9 non-photosensitive trichothiodystrophy, caused by a homozygous variant in the MARS1 gene. That patient had atypical features including long hair, normal eyebrow and eyelash density, and precocious puberty, underscoring the broad clinical spectrum of the disorder.
No drug treatment is mentioned in any of these abstracts. The molecular work clarifies that photosensitive TTD arises from defective TFIIH, but no intervention that restores TFIIH function or compensates for the DNA repair or transcription deficit has been tested in these reports. The abstracts are descriptive case series and molecular reviews; they contain no survival data, no response rates, and no sample sizes beyond single cases or sibling pairs.
What is missing is any preclinical or clinical trial of a drug, any attempt to stratify patients by specific TFIIH subunit mutation, and any funding or trial design aimed at correcting the underlying nucleotide excision repair or transcription defect. Without such work, the molecular understanding of TFIIH dysfunction in photosensitive TTD has not yet been translated into a candidate therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Molecular Genetics · 2009 · 74 citations
Trichothiodystrophy view from the molecular basis of DNA repair/transcription factor TFIIH
AbstractTrichothiodystrophy (TTD) is a rare autosomal recessive disorder characterized by brittle hair and also associated with various systemic symptoms. Approximately half of TTD patients exhibit photosensitivity, resulting from the defect in the nucleotide excision repair. Photosensitive TTD is due to mutations in three genes encoding XPB, XPD and p8/TTDA subunits of the DNA repair/transcription factor TFIIH. Mutations in these subunits disturb either the catalytic and/or the regulatory activity of the two XPB, XPD helicase/ATPases and consequently are defective in both, DNA repair and transcription. Moreover, mutations in any of these three TFIIH subunits also disturb the overall architecture of the TFIIH complex and its ability to transactivate certain nuclear receptor-responsive genes, explaining in part, some of the TTD phenotypes.
BMJ Case Reports · 2018 · 7 citations · open access
PIBIDS syndrome in two Brazilian siblings
AbstractTrichothiodystrophy is a rare condition associated with autosomal recessive or X-linked dominant variants in the ERCC2, ERCC3, GTF2H5, MPLKIP, RNF113A or GTF2E2 genes. The genes associated to photosensitive trichothiodystrophy encode subunits of transcription factor IIH, involved in the nucleotide excision repair pathway. The disease is characterised by cysteine-deficient brittle hair along with other neuroectodermal abnormalities. It has a variable clinical expression and some cases might be associated with photosensitivity, resulting in the acronym PIBIDS ( photosensitivity , ichthyosis , brittle hair , intellectual impairment , decreased fertility and short stature ). We report clinical findings of two siblings diagnosed with trichothiodystrophy associated with marked photosensitivity.
Second Case of Type 9 Non‐Photosensitive Trichothiodystrophy Caused by Homozygous Variant in the <i>MARS1</i> Gene
AbstractTrichothiodystrophy exhibits a broad clinical spectrum, and cases with an uncommon phenotype can go unnoticed, complicating the diagnosis. We present the second case of type 9 non-photosensitive trichothiodystrophy caused by a homozygous variant in the MARS1 gene. It presented with atypical features, including long hair, normal hair density of eyebrows and eyelashes, and precocious puberty.
Photosensitive Trichothiodystrophy with Complex Cerebral Abnormalities
AbstractAims: Trichothiodystrophy (TTD) is a rare ectodermal disorder with congenital hair dysplasia and autosomal recessive inheritance. Tiger tail banding under polarized light and low sulfur content of hair plus trichoschisis are pathognomic for this disorder. Most mutations are found in the ERCC2/XPD and ERCC/XPB gene in the long arm of chromosome 19. In the case of photosensitivity, the disease is typically associated with additional DNA repair defects which can be classified by distinct mutations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
